scholarly journals Heterogeneous Tumor Subpopulations Cooperate to Drive Invasion

Cell Reports ◽  
2014 ◽  
Vol 8 (3) ◽  
pp. 688-695 ◽  
Author(s):  
Anna Chapman ◽  
Laura Fernandez del Ama ◽  
Jennifer Ferguson ◽  
Jivko Kamarashev ◽  
Claudia Wellbrock ◽  
...  
Keyword(s):  

2012 ◽  
Vol 198 (3) ◽  
pp. 281-293 ◽  
Author(s):  
Irène Baccelli ◽  
Andreas Trumpp

The cancer stem cell (CSC) concept, which arose more than a decade ago, proposed that tumor growth is sustained by a subpopulation of highly malignant cancerous cells. These cells, termed CSCs, comprise the top of the tumor cell hierarchy and have been isolated from many leukemias and solid tumors. Recent work has discovered that this hierarchy is embedded within a genetically heterogeneous tumor, in which various related but distinct subclones compete within the tumor mass. Thus, genetically distinct CSCs exist on top of each subclone, revealing a highly complex cellular composition of tumors. The CSC concept has therefore evolved to better model the complex and highly dynamic processes of tumorigenesis, tumor relapse, and metastasis.



2018 ◽  
Author(s):  
Zeya Wang ◽  
Shaolong Cao ◽  
Jeffrey Morris ◽  
Jaeil Ahn ◽  
Rongjie Liu ◽  
...  


Oncology ◽  
2021 ◽  
Vol 99 (10) ◽  
pp. 652-658
Author(s):  
Jhe-Cyuan Guo ◽  
Chen-Yuan Lin ◽  
Chia-Chi Lin ◽  
Ta-Chen Huang ◽  
Ming-Yu Lien ◽  
...  

<b><i>Introduction:</i></b> Heterogeneous tumor response has been reported in cancer patients treated with immune checkpoint inhibitors (ICIs). This study investigated whether the tumor site is associated with the response to ICIs in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC). <b><i>Methods:</i></b> Patients with ESCC who had measurable tumors in the liver, lung, or lymph node (LN) according to the response evaluation criteria in solid tumors (RECIST) 1.1 and received ICIs at 2 medical centers in Taiwan were enrolled. In addition to RECIST 1.1, tumor responses were determined per individual organ basis according to organ-specific criteria modified from RECIST 1.1. Fisher test or χ<sup>2</sup> test was used for statistical analysis. <b><i>Results:</i></b> In total, 37 patients were enrolled. The overall response rate per RECIST 1.1 was 13.5%. Measurable tumors in the LN, lung, and liver were observed in 26, 17, and 13 patients, respectively. The organ-specific response rates were 26.9%, 29.4%, and 15.4% for the LN, lung, and liver tumors, respectively (<i>p</i> = 0.05). The organ-specific disease control rates were 69.2%, 52.9%, and 21.1% for the LN, lung, and liver tumors, respectively (<i>p</i> = 0.024). Five (27.8%) among 18 patients harboring at least 2 involved organs had heterogeneous tumor response. <b><i>Conclusion:</i></b> The response and disease control to ICIs may differ in ESCC tumors located at different metastatic sites, with a lesser likelihood of response and disease control in metastatic liver tumors than in tumors located at the LNs and lung.



Drug Delivery ◽  
2019 ◽  
Vol 26 (1) ◽  
pp. 404-415 ◽  
Author(s):  
Margo Steuperaert ◽  
Charlotte Debbaut ◽  
Charlotte Carlier ◽  
Olivier De Wever ◽  
Benedicte Descamps ◽  
...  


Author(s):  
Jerome Griffon ◽  
Delphine Le Guillou-Buffello ◽  
Oumeima Laifa ◽  
Maxime Doury ◽  
Alexandre Dizeux ◽  
...  


2001 ◽  
Vol 31 (3) ◽  
pp. 300-301 ◽  
Author(s):  
Jose M. Garcia ◽  
Jose M. Silva ◽  
Gemma Dominguez ◽  
Javier Silva ◽  
Felix Bonilla








Sign in / Sign up

Export Citation Format

Share Document